At least two conclusions can be drawn from these studies. The first conclusion is that the mechanism of protection by activated protein C cannot be only via prevention of fibrin formation. The application of DEGR-Xa to the investigation of the process of gram-negative septic shock has allowed us for the first time to demonstrate clearly that, although coagulation occurs in gram-negative sepsis, fibrin formation per se is of limited importance in determining the lethality of E coli in this primate model. Thus, while there is a significant difference in the number of animals surviving less than 15 hours in the control group versus. International The International region reported year on year turnover growth of three per cent. Strong growth in Asia Pacific up eight per cent and Latin America up eight per cent, was offset by flat sales in Australia and declines of five per cent in Sub-Sahahra Africa, eight per cent in the Middle East North Africa and 11 per cent in Canada. In Canada, the sales decline was due to generic erosion of Paxil IR, excluding this element, Canada grew 4.5 per cent. Japan recorded turnover growth of five per cent, despite routine government price reductions being implemented in 2004. Paxil up 25 per cent, Serevent up 74 per cent and Valterx up 16 per cent performed particularly well offsetting small declines in Zantac and Zovirax. Across all markets in International, the key products driving growth were Seretide, which grew 15 per cent to record sales of 229 million, Avandia Avandamet, which grew 62 per cent to 161 million and the vaccines franchise, which recorded growth of 21 per cent and achieved sales of 405 million. Consumer Healthcare sales and sumycin.

The strong growth of GlaxoSmithKline's epilepsy and bi-polar disorder treatment Lamictal continues, with sales up 32 per cent to 678 million. Ongoing US growth, up 49 per cent to 414 million, is being driven by the indication for the maintenance treatment of bi-polar disorder received last year. Anti-virals Global HIV product sales rose four per cent to 1.5 billion and sales in the USA increased four per cent to 747 million. GlaxoSmithKline continues to grow its HIV franchise, despite the launch of several new products by competitors. HIV performance was enhanced by the launch of Epzicom, a new combination product Epivir Ziagen ; in the USA in August 2004 and in the EU under the name Kivexa ; in January 2005. Sales of the herpes treatment Valtex exceeded 500 million for the first time in 2004 up 24 per cent to 571 million ; . Performance is being driven by the USA up 30 per cent to 369 million ; where the product is the clear market leader in treatments for genital herpes. Anti-bacterials Anti-bacterial sales declined nine per cent worldwide and 24 per cent in the USA reflecting generic competition in all regions. Metabolic The diabetes treatments Avandia Avandamet continue to perform very strongly, with overall sales of 1.1 billion up 32 per cent ; . Sales in the USA grew 26 per cent to 852 million. Encouragingly, Avandia Avandamet are also growing very strongly in Europe and International markets with sales up 49 per cent and 62 per cent, respectively. Strong performance in these markets is driven by the growing acceptance amongst opinion leaders and physicians of the benefits of these new products in improving control for diabetic patients. Vaccines The vaccines business had a strong year, with sales up 11 per cent to 1.2 billion. Several key products are driving growth Pediarix Infanrix up 12 per cent to 357 million, Priorix up 14 per cent to 95 million and Fluarix up 38 per cent to 79 million. Oncology and emesis Sales of Zofran grew eight per cent to 763 million, driven by the US performance, up 10 per cent to 565 million. Cardiovascular and urogenital In 2004, Coreg for heart disease ; sales grew 34 per cent to 432 million. Other therapeutic areas Sales of Zantac fell 12 per cent to 273 million with declines in all regions.
USE FOR SUPPRESSION OF RECURRENT GENITAL HERPES IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS HIV ; Valtrex was evaluated in a multicenter, randomized, double-blind, placebo controlled study for the suppression of recurrent ano-genital HSV infections in HIV-infected individuals 14, 15 ; . The proportion of patients recurrence free of ano-genital HSV at 6 months was significantly higher in patients receiving Valtrex compared with placebo 65% vs. 26%, p 0.001 ; . The time to first ano-genital HSV recurrence was significantly shorter in the placebo group compared to the group receiving Valtrex [HR: 0.20 95% CI: 0.13, 0.30, p 0.001 ; ]. Valtrex was well tolerated, with adverse events occurring at a similar frequency across treatment groups when duration of follow-up was considered. Specific study results can be found in Table 5. The comparative efficacy and safety of Valtrex vs. acyclovir for the suppression of recurrent HSV in HIVinfected patients was studied in a double-blind, randomized clinical trial 16, 17, 18, ; . Clinically, Valtrex PO 500 mg twice daily was shown to be at least as effective as acyclovir PO 400 mg twice daily in delaying the time to first recurrence of genital herpes in HIV-infected patients CD4 + lymphocyte count 100 cells mm3 ; . Valtrex 500 mg twice daily was superior to Valtrex 1000mg once daily p 0.001 ; . The nature and incidence of adverse events was similar among treatment groups. Headache and nausea were the most commonly reported adverse events. However, a low HSV recurrence rate 18% ; and a high patient withdrawal rate 43% ; compromised the power of the study to detect statistically significant differences between drug regimens. The high patient withdrawal rate was possibly due to the concurrent introduction of protease inhibitor clinical trials in this patient population during this time period. Patients who enrolled in protease inhibitor trials were no longer eligible to continue the trial with Valtrex, and hence were dropped from the study population. In addition, because over 70% of patients did not have a recurrence during the study period, the median time to first recurrence no. of days ; was unable to be calculated. Thrombotic thrombocytopenic purpura hemolytic uremic syndrome TTP HUS ; , in some cases resulting in death, has occurred in patients with advanced HIV disease and also in allogeneic bone marrow transplant and renal transplant recipients participating in clinical trials of Valtrex at doses of 8 grams per day. No reports of thrombotic microangiopathy TTP HUS ; attributed to Valtrex or acyclovir was reported in this study and cefixime. More and more americans are waking up to the reality of our medical community.
GSK's underlying growth driven by strong sales performance of key products: Seretide Advair 2.5 billion ; up 19% Vaccines 1.2 billion ; up 11% Avandia Avandamet 1.1 billion ; up 32% Lamictal 0.7 billion ; up 32% Valtrex 0.6 billion ; up 24% Coreg 0.4 billion ; up 34 and flagyl. NSAIDs Diclofenac Potassium Diclofenac Sodium Diflunisal Etodolac Fenoprofen Flurbiprofen Ibuprofen Indomethacin Indomethacin SR Ketoprofen Ketoprofen ER Ketorolac Meclofenamate Sod. Nabumetone Naproxen Naproxen Sodium Oxaprozin Piroxicam Sulindac Tolmetin Sodium Macrolides Ketolides Azithromycin Biaxin XL Clarithromycin EryPed Ery-Tab Erythromycin Base Erythromycin Estolate Erythromycin Ethylsuc. Erythromycin Stearate Erythrocin Stearate Erythromycin & Sulfisox. Quinolones, 2nd and 3rd Generation Avelox Ciprofloxacin Factive Levaquin Ofloxacin ANTIFUNGALS, ORAL Onychomycosis Agents OPIOIDS, EXTENDED RELEASE Avinza Duragesic Patch Kadian Morphine Sulfate ER Generic MS Contin Gris-Peg Griseofulvin Lamisil ANTIVIRALS, ORAL Herpes Antivirals Acyclovir Famvir Valtrex Captopril Enalapril Enalapril HCTZ Lisinopril Lisinopril HCTZ ACEI, CALCIUM CHANNEL BLOCKER COMBINATIONS Lotrel Tarka ANGIOTENSIN RECEPTOR BLOCKERS Avalide Avapro Benicar Benicar HCT Cozaar Diovan Diovan HCT Hyzaar Micardis Micardis HCT Teveten Teveten HCT BETA BLOCKERS Acebutolol Atenolol Atenolol Chlorthalidone Betaxolol Bisoprolol Fumarate Bisoprolol HCTZ Labetolol Metoprolol Tartrate Nadolol Pindolol Propranolol Propranolol HCTZ Sotalol Timolol Coreg regular release formulation Use of Coreg reserved for treatment of hypertension accompanied by heart failure. CALCIUM CHANNEL BLOCKERS, DIHYDROPYRIDINE Dynacirc Dynacirc CR Nicardipine Nifedical XL Nifedipine ER and SA Norvasc Plendil CALCIUM CHANNEL BLOCKERS, NONDIHYDROPYRIDINES Cartia XT Diltia XT Diltiazem Diltiazem ER and XR Taztia XT Verapamil Verapamil ER Verapamil SR LIPOTROPICS Bile Acid Sequestering Resins Cholestyramine Cholestyramine Light Colestid Welchol Fibric Acid Derivatives Gemfibrozil Lofibra Tricor Niacin Derivatives Niacor Niaspan Statins Advicor Altoprev Crestor Lescol Lescol XL Lipitor Lovastatin Pravastatin Simvastatin. Macrolides Azithromycin generic ; Clarithromycin XL generic ; Erythromycin generic ; Erythromycin Sulfisoxazole generic ; Penicillins Amoxicillin generic ; Amoxicillin Clavulanate Augmentin XR. generic ; Ampicillin generic ; Dicloxacillin generic ; Penicillin generic ; Quinolones Ciprofloxacin XR generic ; Levofloxacin Levaquin ; Sulfonamides Erythromycin Sulfisoxazole generic ; Sulfamethoxazole Trimethoprim generic ; Sulfisoxazole generic ; Tetracyclines Doxycycline hyclate generic ; Minocycline generic ; Tetracycline generic ; ANTIFUNGAL AGENTS ORAL ; Clotrimazole generic ; Fluconazole generic ; Griseofulvin generic ; Itraconazole generic ; Ketoconazole generic ; Nystatin generic ; Terbinafine Lamisil generic ; ANTI-MALARIALS Chloroquine generic ; Mefloquine generic ; Primaquine Primaquine ; Pyrimethamine Daraprim ; Pyrimethamine Sulfadoxine Fansidar ; Quinine generic ; ANTI-TUBERCULOSIS AGENTS Ethambutol generic ; Ethionamide Trecator-SC ; Isoniazid generic ; Pyrazinamide generic ; Rifabutin Mycobutin ; Rifampin generic ; OTHER ANTI-INFECTIVES Clindamycin generic ; Iodoquinol Yodoxin ; Metronidazole generic ; Trimethoprim generic ; ANTI-NEOPLASTIC AGENTS All FDA-approved, self-administered injectable and oral anti-neoplastic agents are eligible for coverage under the prescription drug benefit. May be subject to PAB. ANTIVIRAL AGENTS Acyclovir generic ; Amantadine generic ; Ganciclovir generic ; Interferon Alfa-2A Roferon-A ; Interferon Alfa-2B Intron A ; Interferon Alfa-2B Ribavirin Rebetron ; Interferon Alfacon-1 Infergen ; Lamivudine Epivir HBV ; Peginterferon Alfa-2B Peg-Intron ; Peginterferon Alfa-2A Pegasys ; Ribavirin generic ; Valacyclovir Valtrex ; Valganciclovir Valcyte and chloramphenicol.

Further Information Pharmaceutical companies are not in a position to give people individual diagnosis or medical advice. Your doctor or pharmacist is the best person to give you individual advice. You may also be able to find general information about your disease and its treatment from books, for example in public libraries. This leaflet was prepared on 22 January 2004 The information provided applies only to: Valtrex TM tablets. TMValtrex is a trade mark of the GlaxoSmithKline Group of Companies.

Genital herpes is a sexually transmitted infection, most commonly caused by herpes simplex virus 2 HSV-2 ; . Its close relative, HSV-1, causes herpes of the mouth, lips and skin, like cold sores. Genital herpes recur and there is no cure. Symptoms include single or multiple small blisters that open and become sores after a few days. Other symptoms include swelling of the vulva, fever and enlarged and tender lymph nodes in the stomach and groin area abdomen ; . The most common sites for herpes in women are the labia majora the vagina's "outer lips" ; , labia minora the "inner lips" ; and butt. Though herpes may lay dormant for long periods, it can appear again at anytime, especially for those with a weak immune system. Sexual contact should be avoided while sores are present because of the increased risk of passing herpes onto others. However, the virus may also shed when a person has no symptoms or sores. For HIV-positive women, the painful sores in and around the genitals or anus tend to be more frequent, last longer and need higher doses of treatment. Having sores that persist for more than a month is considered an AIDSdefining illness. Oral acyclovir Zovirax ; and famciclovir Famvir ; are used to treat herpes. Valacyclovir Valtrex ; requires fewer pills and thus is easier to incorporate into treatment regimens where many other pills are being used. However, it is not recommended for use in people with immune suppression. Some still use valacyclovir, however, and monitor carefully for side effects. For women with frequent outbreaks, daily acyclovir therapy may help prevent them. If herpes stops responding to acyclovir sores don't go away within two weeks ; , other therapies are available. These include intravenous foscarnet Foscavir ; . Many of the same tips provided for prevent-ing yeast infections can help in making you more comfortable and aid in healing if you are experiencing a herpes outbreak. See the box on page 2 for these tips. School athletes [40, 43] and are more likely to result from lateral neck flexion with shoulder depression. Cervical nerve-root compression is more common in college and professional football players [40, 43], particularly those who have recurrent or chronic stingers. It may be associated with cervical disk disease, cervical canal stenosis, and neural foraminal stenosis [4042], and may result from neck extension or forceful lateral neck flexion. It is possible that any or all of these mechanisms may account for a particular athlete's symptoms. Symptoms involve a single upper extremity; bilateral or lower extremity symptoms should raise the possibility of a cervical spinal cord injury rather than a stinger syndrome. There may be rapid onset of burning pain in the shoulder [34, 39], or from the neck [32] or supraclavicular area [33] down the arm to the hand [32, 33, 37, 43] or fingers [39, 44, 45]. Paresthesias or anesthesia may occur throughout the upper extremity [32, 33, 39], but more commonly occurs in a C5 dermatomal distribution [43]. Alternatively, there may be no sensory deficit, only pain [37, 38]. The athlete may shake the arm [33] or exhibit a dropped shoulder [37, 38]. Weakness following a stinger is variable, ranging from mild weakness in a myotomal pattern [4345] to inability to move the entire arm [32, 33], and the athlete may exit the contest supporting the affected arm with the contralateral arm [33, 45, 46]. There may be no evidence of weakness immediately after the injury, only to develop later [33, 37]. Muscles commonly involved include the deltoid, biceps, supraspinatus, and infraspinatus [43, 45], causing weakness of shoulder abduction, elbow flexion, and upper arm external rotation. Symptoms are usually transient, lasting only seconds to minutes. There is usually no associated neck pain or limitation of neck movement. Assessment and Management On-field evaluation begins with establishment of the mechanism of injury-- either lateral flexion shoulder depression or extension compression. The athlete should describe the location of symptoms and their duration if they have resolved. Otherwise the athlete should be monitored for resolution of symptoms. The cervical spine should be evaluated by palpation for tenderness, edema, evidence of structural damage, or muscle spasm. The supraclavicular fossa should also be examined in like fashion. If there is no concern for cervical fracture, active range of motion within the limitation of pain should be assessed to include rotation, lateral flexion, anteroflexion, and extension. A full neurological examination should be performed, with specific attention to strength testing in all muscle groups, full sensory examination, and muscle stretch reflex testing. The contralateral extremity should serve as a normal control. If symptoms or deficits involve the bilateral upper extremities or include one or both lower extremities, or if there is concern for other serious structural damage, the cervical spine should be immobilized and spine precautions instituted. The athlete should then be transported in a stable fashion by qualified personnel to a facility capable of appropriate neurological and neurosurgical evaluation and treatment.
Prevent embolic stroke 20-30% PFO rate ; . Prevent the post thrombotic syndrome.
Can herpes kill you 02 may 2008 : 18 utc herpes valtrex : where can give you had sufferers to call a person often grouped together as severe symptoms.

Erectile dysfunction viagra hair loss propecia herpes valtrex smoking cessation chantix welcome to the centerformenshealth men’ s fitness and health started in 1999, the center for men's health had a vision to deliver quality men’ s fitness and health care online with a patient centered focus.

Valtrex hsv 1 Tremendous difficulty for the treatment of individual patient, and its widespread dissemination would pose a serious threat to the achievement of leprosy control. RMP-resistant leprosy was first documented in the 1970s 31 ; . It was rare 31, 32 ; , probably because, in that era, RMP was seldom employed for the treatment of leprosy. Later, it was reported that, among a total of 404 MB patients who had been treated with various RMP-containing regimens, 39 relapsed and 22 were found to harbor organisms resistant to RMP, as proven by the mouse footpad technique 33 ; . Virtually all of the resistant strains were isolated from patients who had been treated with RMP only after they had relapsed after long-term monotherapy with dapsone or other sulfones, and almost all of the strains were also resistant to dapsone, indicating that these patients had in effect been receiving RMP monotherapy. Because many of the 22 patients developed RMP-resistance in the decade after beginning treatment with RMP 33 ; , it appeared that RMP-resistance could emerge rather rapidly among patients whose treatment regimens were inappropriate. Although more than 10 million leprosy patients in the world have completed treatment with MDT, and RMP-resistant leprosy has not been reported among these patients 2 ; , one must be cautious in interpreting the findings. First, post-MDT surveillance for relapse is no longer carried out in most routine programs. Second, the standard means of diagnosing drug-resistant leprosy has required use of the mouse footpad technique; however, the great majority of the mouse footpad laboratories established for surveys of dapsone-resistance have disappeared during the last decade, which coincided with intensive implementation of MDT. As a result, RMP-susceptibility testing is rarely carried out, and the results are not always reliable. In fact, one cannot exclude the possibility that a number of RMP-resistant leprosy patients are currently undetected. Before RMP-resistance becomes so frequent that it threatens leprosy control, more solid information about its magnitude should be collected in different parts of the world. Although it is no longer feasible to undertake a relatively large-scale survey of RMP-resistant leprosy by means of the mouse footpad technique, PCR-based DNAsequence analysis of the rpoB gene of M. leprae represents a cost-effective alternative technique 34-36 ; . At this stage, surveys of RMP-resistance should focus on MB patients who have relapsed after completion of MDT, and surveillance for the emergence of RMP-resistance among relapsed MB patients should be carried out by special centers. For this purpose, a proportion of MB patients should be systematically examined clinically and bacteriologically after completion of MDT, and skin-biopsy specimens should be obtained from those patients suspected of relapse for DNA sequence analysis of the rpoB gene of M. leprae 34-36 ; . MDT was developed mainly because of the widespread emergence of dapsone resistance, and the MDT regimens were designed on the principle that they would be effective against all the strains of M. leprae, regardless of their susceptibility to dapsone 1, 2 ; . Hence, in the MDT era, whether the global prevalence of dapsone-resistance is. Company has taken unprecedented steps in promoting the replacement of Zovirax, by advertising on television for viewers to call a toll-free number to qualify for free-trial samples, by taking out full page ads in numerous magazines also including the free-trial offer ; , and by arranging for the inclusion of glossy insert ads for my campus newspaper and I would bet other campus newspapers as well ; . I have never seen such an advertising blitz for a prescription drug before. A little explanation is in order here. It begins with the fact that the active ingredient of Zovirax acyclovir, which I will discuss shortly ; was patented in 1980 by Burroughs Wellcome Co. a.k.a., GlaxoSmithKline ; . This patent, No. 4199574, "Methods and compositions for treating viral infections and guanine acyclic nucleosides" ; recently expired. Such patents are generally good for 17 years. ; This means that other pharmaceutical companies can now manufacture generic acyclovir, which means that it is currently available more cheaply than it was under the name Zovirax. Since GlaxoSmithKline has `lost' ownership of the product, the company has invented replacement products which it has also patented. So now the company promotes the replacement products, which are covered under current patents, more or less going about their business as if Zovirax never existed. So what are the replacement products? The main one is called Valtrex, which contains the active ingredient valacyclovir hydrochloride. It is no coincidence that this name is so similar to acyclovir. In non-technical lingo, I would describe valacyclovir as the same thing as acyclovir but with an extra chemical doohickey attached to it in this case, the doohickey is an amino acid called L-valine ; . Indeed, as soon as valacyclovir goes into the body, it immediately loses the doohickey and becomes acyclovir itself! So the most significant difference between the two is that GlaxoSmithKline holds a current patent on one valacyclovir ; but not on the other acyclovir ; . That is why the company is blitzing the market with their `new' treatment for herpes. This drug is covered by patent number 4957924 "Therapeutic valine esters of acyclovir and pharmaceutically acceptable salts thereof" ; , which was granted in 1990. You can expect yet another `new' product to come along before this patent expires. ; For the purposes of this book, therefore, my discussion of Zovirax applies equally to Valtrex and any other similar new product that is derived from acyclovir. Medical Economics Company of Montvale, New Jersey, publishes the Physicians' Desk Reference, which describes drug dosages, effects, and side effects. This is an important resource for every doctor and every patient, although patients do not generally own it. You can find one in the reference section of almost any public library. In the 1996 edition, you will. The criterion used is formed into a question: what is the probability that a `minimally acceptable' candidate will answer this item correctly.

Dosage information on valtrex What are the possible side effects of VALTREX? Kidney failure and nervous system problems are not common, but can be serious in some patients taking VALTREX. Nervous system problems include aggressive behavior, unsteady movement, shaky movements, confusion, speech problems, hallucinations seeing or hearing things that are really not there ; , seizures, and coma. Kidney failure and nervous system problems have happened in patients who already have kidney disease and in elderly patients whose kidneys do not work well due to age. Always tell your healthcare provider if you have kidney problems before taking VALTREX. Call your doctor right away if you get a nervous system problem while you are taking VALTREX. Common side effects of VALTREX include headache, nausea, stomach pain, vomiting, and dizziness. Side effects in HIV-infected adults include headache, tiredness, and rash. These side effects are usually mild and usually do not cause patients to stop taking VALTREX. Other less common side effects include painful periods in women, joint pain, depression, low blood cell counts, and changes in tests that measure how well the liver and kidneys work. Talk to your healthcare provider if you develop any side effects that concern you. These are not all the side effects of VALTREX. For more information ask your healthcare provider or pharmacist. How should I store VALTREX? Store VALTREX at room temperature, 59 to 77F 15 to 25C ; . Keep VALTREX in a tightly closed container. Do not keep medicine that is out of date or that you no longer need. Keep VALTREX and all medicines out of the reach of children. Schistosomiasis and pre-school children and women at child-bearing age for soil-transmitted helminths. 5.3: Chemotherapy and health education are best delivered through school-based programs that include an outreach component to cover nonenrolled school-age children in the community. 5.4: More attention should be paid to the collection of accurate and valid information about prevalence and intensity of infection. Data based on cases presenting for treatment could be misleading. Surveys on schoolchildren using standard methods could produce representative and manageable small samples that are appropriate for estimation of the prevalence and intensity of infection. 5.5: Governorates coordinators of schistosomiasis control should be involved in developing plans of action for their respective governorates. This should best be done in a national workshop. 5.6: Health education on schistosomiasis should be activated and expanded to involve adult education and religious preachers. Health education messages should aim at creation of a demand for chemotherapy , emphasizing the need for treatment and it impact on morbidity. 5.7: Training activities should be geared to newly-adopted control strategies: Training of laboratory technicians should cover identification and quantification of other soil-trasmitted helminths and the use of regeant strips to detect hematuria . Medical assistants and general practitioners should be trained in the management of schistosomiasis and soiltransmitted heminthiases. The Manager and deputy Manager could benefit from an external study visit to one of the countries where a schoolbased control program is being implemented. 5.8: Operational research with relevance to schistosomiasis control in Yemen should be encouraged especially in collaboration with the academic institutions in Yemen . Among topics that could be of interest : Impact of the new dams in Yemen on the transmission of Schistosomiais. Evaluation of different methods of health education Evaluation of school-based programs for control of shistosomiasis and soil-transmitted helminths Economic impact of schistosomiasis and soil transmitted helminths in Yemen Cost-effectiveness of different methods of surveillance and delivery of chemotherapy . 5.9: Health care facilities especially Health Centers and Health Units should undertake a greater role in the management of cases of schistosomiasis. Valtrex valacyclovir hci 500mg Valyrex, caltrex, vqltrex, valtrez, valttex, vaktrex, vvaltrex, valtre, valgrex, valtdex, valltrex, valtrfx, valt4ex, galtrex, avltrex, faltrex, valtres, valt5ex, valtrsx, vwltrex, valtrxe, valtr3x, vsltrex, valrex, valrtex, valtex, altrex, vaaltrex. Cheap valtrex canada Buy generic valtrex without a prescription, how to take valtrex 1gm, valtrex canada no prescription, valtrex prescription medication and valtrex dosage shingles. Valtrex hpv treatment, valtrex hsv 1, dosage information on valtrex and valtrex valacyclovir hci 500mg or cheap valtrex canada. Generic valtrex medication Nephro hydrosis, phenytoin onset, tobramycin bausch lomb, prematurity icd 9 code and buspar medication side effects. Peter mansfield bio, lacrosse for leukemia 2006, medical history hillary clinton and what is protonix used for or phenolphthalein side effects.